News

Video

Managing Adverse Events in Patients Receiving Later Line Systemic Therapy for Metastatic TNBC

Author(s):

Nour Abuhadra, MD

Dr. Noor Abuhadra discusses managing adverse events in patients receiving TRODELVY (sacituzumab govitecan), a later-line systemic therapy for metastatic triple-negative breast cancer. Shay Elkins, a patient, shares her experience with significant side effects including diarrhea, low white blood cell counts, and hair loss, while Dr. Abuhadra emphasizes the need for proactive management of these issues to maximize treatment time and maintain quality of life.

Related Videos
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Image of a woman with light shoulder-length hair, wearing rectangular glasses.
Image of man with grey hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of a woman with wavy blonde hair wearing glasses.
Image of a woman with tied back hair, wearing pearl earrings.
Related Content
"FDA" text.
January 17th 2025

FDA Approves Datroway for HR+, HER2- Breast Cancer

Alex Biese
Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Image of pills that spell "side FX"
January 15th 2025

Elinzanetant May Treat Hot Flashes Caused by Breast Cancer Treatment

Spencer Feldman
Elinzanetant significantly reduced the frequency and severity of hot flashes in women with breast cancer who were undergoing hormone therapy.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
An image of a doctor and patient talking with one another.
January 9th 2025

Minoxidil May Safely Aid in Hair Growth for Patients With Breast Cancer

Alex Biese
Low-dose oral minoxidil, the hair growth drug that is the active ingredient in Rogaine, may be safe and effective for patients with breast cancer.
An image of a doctor looking at a breast cancer scan.
January 7th 2025

CBD Use Found to Be Safe Among Patients with Breast Cancer, Prompts Further Study

Alex Biese
CBD consumption was safe but did not have a statistically significant reduction in scan-related anxiety versus placebo for patients with breast cancer.